Testa Ugo, Pelosi Elvira, Castelli Germana, Chiusolo Patrizia
Istituto Superiore Sanità, Roma, Italy.
Department of Radiological and Hematological Sciences, Catholic University, Rome, Italy.
Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024070. doi: 10.4084/MJHID.2024.070. eCollection 2024.
Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3 T cells and CD19 B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual disease (MRD)-negative response rates and long-term overall survival have been observed in B-ALL patients who received this drug. These therapeutic successes have led to FDA approval for refractory/relapsed and MRD-positive B-ALL patients. Furthermore, recent studies in newly diagnosed B-ALL patients have led in Philadelphia chromosome-positive patients to the development of chemotherapy-free regimens based on tyrosine kinase inhibitors plus Blinatumomab and in Philadelphia chromosome-negative patients to improvement in outcomes using chemotherapy regimens that have incorporated Blinatumomab in the consolidation phase of treatment.
博纳吐单抗是一种CD19-CD3双特异性T细胞衔接器（BiTE），有两个重组单链可变片段，可暂时连接CD3 T细胞和CD19 B细胞，导致T细胞介导的肿瘤性B细胞裂解。在接受该药物治疗的B-ALL患者中，观察到微小残留病（MRD）阴性缓解率提高和长期总生存率提高。这些治疗成功促使美国食品药品监督管理局（FDA）批准该药物用于难治性/复发性和MRD阳性的B-ALL患者。此外，最近针对新诊断的B-ALL患者开展的研究，在费城染色体阳性患者中促成了基于酪氨酸激酶抑制剂加博纳吐单抗的无化疗方案的开发，在费城染色体阴性患者中促成了通过在巩固治疗阶段纳入博纳吐单抗的化疗方案改善治疗结果。
